|
|
||||||||
1Department of Molecular Physiology and Biophysics, and 2Diabetes Research and Training Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232
Submitted 15 July 2004 ; accepted in final form 10 August 2004
Intraportal delivery of serotonin enhanced net hepatic glucose uptake (NHGU) during a hyperinsulinemic hyperglycemic clamp, but serotonin elevated catecholamines and can cause gastrointestinal distress. We hypothesized that the selective serotonin reuptake inhibitor (SSRI) fluvoxamine would enhance NHGU without side effects. Arteriovenous difference and tracer ([3-3H]glucose) techniques were used in conscious 42-h-fasted dogs. Experiments consisted of equilibration (120 to 30 min), basal (30 to 0 min), and experimental (EXP; 0270 min) periods. During EXP, somatostatin, fourfold basal intraportal insulin, basal intraportal glucagon, and peripheral glucose (to double the hepatic glucose load) were infused. Saline (SAL) was infused intraportally during 090 min (P1), and fluvoxamine was infused intraportally at 0.5, 1, and 2 µg·kg1·min1 from 90 to 150 (P2), 150 to 210 (P3), and 210 to 270 (P4) min, respectively, in the FLUV group (n = 8). The SAL group (n = 9) received intraportal saline during 0270 min. NHGU in SAL was 13.9 ± 1.7 and 17.0 ± 2.0 µmol·kg1·min1 in P3P4, respectively, while NHGU in FLUV averaged 19.7 ± 2.8 and 26.6 ± 3.0 µmol·kg1·min1 (P < 0.05 vs. SAL). Net hepatic carbon retention was greater (P < 0.05) in FLUV than in SAL (17.6 ± 2.6 vs. 13.9 ± 2.7 and 23.8 ± 3.0 vs. 14.4 ± 3.3 µmol·kg1·min1 in P3P4, respectively), and final hepatic glycogen concentrations were 50% greater in FLUV (P < 0.005). Nonhepatic glucose uptake was greater in SAL than in FLUV at 270 min (P < 0.05). Catecholamine concentrations remained basal, and the animals evidenced no distress. Thus fluvoxamine enhanced NHGU and hepatic carbon storage without raising circulating serotonin concentrations or causing stress, suggesting that hepatic-targeted SSRIs might be effective in reducing postprandial hyperglycemia in individuals with diabetes or impaired glucose tolerance.
glycemia; liver; portal vein; hepatic glucose uptake; nonhepatic glucose uptake
This article has been cited by other articles:
![]() |
N. M. Sanders, C. W. Wilkinson, G. J. Taborsky Jr., S. Al-Noori, W. Daumen, A. Zavosh, and D. P. Figlewicz The selective serotonin reuptake inhibitor sertraline enhances counterregulatory responses to hypoglycemia Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E853 - E860. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Moore, K. Kimura, H. Shibata, T. Honjoh, M. Saito, C. A. Everett, M. S. Smith, and A. D. Cherrington Portal 5-hydroxytryptophan infusion enhances glucose disposal in conscious dogs Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E225 - E231. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Moore, C. A. DiCostanzo, D. Dardevet, M. Lautz, B. Farmer, and A. D. Cherrington Interaction of a selective serotonin reuptake inhibitor with insulin in the control of hepatic glucose uptake in conscious dogs Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E556 - E563. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |